Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 55

  • 849 clinical trials
  • 267 recruiting
  • 359 conditions
  • 25 countries

Conditions in this area

359 conditions with trials, the busiest first

Dermatitis atopic89Malignant melanoma79Systemic lupus erythematosus63Psoriasis54Hidradenitis47Psoriatic arthropathy46Systemic scleroderma40Metastatic malignant melanoma32Vitiligo24Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis16Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Basal cell carcinoma12Diabetic foot12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+335

Clinical trials in Skin and subcutaneous tissue disorders

849 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

849 clinical trials

Malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab and Tretinoin in Patients with PD-1 Refractory Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Colorectal cancer+2

Not recruiting

Study of E7386 and Pembrolizumab for Patients with Previously Treated Colorectal Cancer, Melanoma, or Hepatocellular Carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Eisai Limited

Colorectal cancer+6

Not recruiting

Study of INCB099280 and Ipilimumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:INCB099280
  • Sponsor:Incyte Corp.

Hidradenitis

Not recruiting

Study on Amlitelimab for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Porphyria non-acute

Not recruiting

Study of Afamelanotide for Patients with Erythropoietic Protoporphyria (EPP)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Afamelanotide
  • Sponsor:Clinuvel Europe Limited

Gastric cancer+7

Not recruiting

Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Systemic lupus erythematosus

Not recruiting

Study on MK-6194 for Adults with Systemic Lupus Erythematosus

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:MK-6194
  • Sponsor:Merck Sharp & Dohme LLC

Hereditary angioedema with C1 esterase inhibitor deficiency

Not recruiting

Long-term Safety Study of KVD900 for Treating Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema Type I or II

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sebetralstat
  • Sponsor:Kalvista Pharmaceuticals Limited

Skin ulcer

Not recruiting

Study on the Effectiveness and Safety of allo-APZ2-CVU for Healing Chronic Venous Ulcers in Patients with Therapy-Resistant Wounds

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic skin-derived ABCB5-POSITIVE dermal mesenchymal stromal cells
  • Sponsor:Rheacell GmbH & Co. KG

Malignant melanoma

Not recruiting

Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Porphyria non-acute

Not recruiting

Study on the Effects of Dersimelagon Phosphate for Adults and Adolescents with Erythropoietic Protoporphyria or X-Linked Protoporphyria

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dersimelagon Phosphate
  • Sponsor:Tanabe Pharma America Inc.

Acute myeloid leukaemia refractory+3

Not recruiting

Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.